Nath Bio-Genes (India) Ltd — earnings calls

1 quarter summarised from transcripts filed with the exchange, every statement cited. Newest first.

Nath Bio-Genes reported FY26 revenue of INR 4,316 million, up 19% YoY, with EBITDA of INR 525 million at a 12% margin and PAT of INR 384 million at a 9% margin. Management highlighted 22.35% volume growth in cotton, 25% volume growth in paddy, and a 54% volume surge in maize, alongside a first-time INR 15 crore contribution from its Uzbekistan joint venture. Gross margin normalized to 56% from an elevated 63-64% in FY25 due to a richer product and market mix, and management discussed inventory build-up, El Nino preparedness, and plans for FY27 growth.